In Silico藥物發現市場規模、佔有率、按產品、工作流程、標靶治療領域、最終用戶和地區分類的成長分析 - 產業預測，2025 年至 2032 年

2023 年全球In Silico藥物發現市場規模價值 29 億美元，預計將從 2024 年的 32.2 億美元成長到 2032 年的 74.2 億美元，預測期內（2025-2032 年）的複合年成長率為 11.0%。

由於藥物發現資料量的增加和生物資訊技術的進步，預計 2023 年至 2030 年間In Silico藥物發現市場將大幅成長。市場正在利用In Silico策略來識別藥物目標、開發候選分子並最佳化結合特性。以降低再入院率和醫療錯誤為重點的生物標記識別的增加預計將進一步推動市場擴張。計算生物學的重大進步和In Silico設計服務正在使市場變得更具吸引力。然而，價格壓力和開放原始碼軟體的可用性等挑戰可能會阻礙成長。總體而言，製藥公司的藥物發現計劃和研究活動的激增為市場相關人員創造了巨大的商機。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

In Silico藥物發現市場按產品分類的規模

• 市場概況
• 軟體即服務
• 軟體
• 諮詢即服務

In Silico藥物發現市場規模（按工作流程）

• 市場概況
• 臨床前試驗
• 發現
• 臨床試驗

In Silico藥物發現市場規模（按標靶治療領域分類）

• 市場概況
• 代謝紊亂
• HIV
• 感染疾病
• 肌肉骨骼疾病
• 精神障礙
• 神經系統疾病
• 腫瘤疾病

In Silico藥物發現市場規模（按最終用戶分類）

• 市場概況
• 合約研究組織
• 製藥和生物製藥公司
• 學術研究所
• 其他

In Silico藥物發現市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Atomwise（USA）
• Insilico Medicine（Hong Kong）
• Iktos（France）
• Cradle（USA）
• BenevolentAI（UK）
• Schrodinger（USA）
• Cloud Pharmaceuticals（USA）
• Numerate（USA）
• XtalPi（China）
• BenevolentAI（UK）
• Biovista（USA）
• Certara（USA）
• Cloud Pharmaceuticals（USA）
• XtalPi（China）
• Atomwise（USA）
• Exscientia（UK）
• Insilico Medicine（Hong Kong）
• Iktos（France）
• Cradle（USA）

結論和建議

Global Insilico Drug Discovery Market size was valued at USD 2.9 billion in 2023 and is poised to grow from USD 3.22 billion in 2024 to USD 7.42 billion by 2032, growing at a CAGR of 11.0% during the forecast period (2025-2032).

The in-silico drug discovery market is poised for significant growth from 2023 to 2030, driven by the increasing volume of drug discovery data and advancements in bioinformatics technologies. This market leverages in-silico strategies to identify drug targets, develop candidate molecules, and optimize their binding properties. The projected rise in biomarker identification, coupled with a focus on minimizing readmission rates and medical errors, further supports market expansion. Significant advancements in computational biology and cost-effective in-silico designing services enhance market appeal. However, challenges such as pricing pressures and the availability of open-source software may hinder growth. Overall, the surge in drug discovery projects and research activity within pharmaceutical organizations presents considerable opportunities for market players.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insilico Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insilico Drug Discovery Market Segmental Analysis

Global Insilico Drug Discovery Market is segmented by Product, Workflow, Target Therapeutic Area, End User and region. Based on Product, the market is segmented into Software-as-a-Service, Software and Consultancy-as-a-Service. Based on Workflow, the market is segmented into Pre-Clinical Tests, Discovery and Clinical Tests. Based on Target Therapeutic Area, the market is segmented into Metabolic disorders, HIV, Infectious diseases, Musculoskeletal disorders, Mental disorders, Neurological disorders and Oncological disorders. Based on End User, the market is segmented into Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insilico Drug Discovery Market

The global in-silico drug discovery market is expected to experience significant growth in the coming years, primarily driven by advancements in biomarker identification. Additionally, there is a growing emphasis on reducing readmission rates and minimizing medical errors, which further fuels this demand. Innovations in computational technologies within computational biology and enhancements in in-silico drug discovery methodologies also contribute substantially to market expansion. These factors collectively create a robust environment that encourages the adoption of in-silico approaches, ultimately transforming the drug discovery landscape and meeting the evolving needs of the healthcare sector.

Restraints in the Global Insilico Drug Discovery Market

A significant challenge facing the Global Insilico Drug Discovery market is its inherently short lifespan, which serves as a primary restraint. The analysis durations for this technology can vary from tens to hundreds of nanoseconds, contingent upon the complexity of the systems being evaluated and the computational resources available. This brevity poses a substantial issue, as the time frames-ranging from a few milliseconds to several seconds-are often insufficient for precise predictions of protein folding. Consequently, this limitation may hinder the sampling of an adequate number of protein conformations, potentially impacting the accuracy and reliability of drug discovery outcomes.

Market Trends of the Global Insilico Drug Discovery Market

The global in-silico drug discovery market is witnessing significant growth, primarily fueled by the rising adoption of cloud-based solutions that enhance computational capabilities for pharmaceutical researchers. This trend allows for scalable and adaptive computing environments, empowering researchers with virtually unlimited processing power to accelerate drug development processes. Notably, platforms like BT's Cloud Compute life sciences service offer tailored applications that cater to various stages of the drug discovery value chain, enabling seamless compatibility across diverse pipelines. As companies increasingly prioritize tailored solutions, the market is set to expand, driving innovation and efficiency in drug discovery efforts.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Insilico Drug Discovery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Software-as-a-Service
• Software
• Consultancy-as-a-Service

Global Insilico Drug Discovery Market Size by Workflow & CAGR (2025-2032)

• Market Overview
• Pre-Clinical Tests
• Discovery
• Clinical Tests

Global Insilico Drug Discovery Market Size by Target Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Metabolic disorders
• HIV
• Infectious diseases
• Musculoskeletal disorders
• Mental disorders
• Neurological disorders
• Oncological disorders

Global Insilico Drug Discovery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Contract Research Organizations
• Pharmaceutical and Biopharmaceutical Companies
• Academic and Research Institutes
• Others

Global Insilico Drug Discovery Market Size & CAGR (2025-2032)

• North America (Product, Workflow, Target Therapeutic Area, End User)
  • US
  • Canada
• Europe (Product, Workflow, Target Therapeutic Area, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Workflow, Target Therapeutic Area, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Workflow, Target Therapeutic Area, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Workflow, Target Therapeutic Area, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Atomwise (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iktos (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cradle (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Schrodinger (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cloud Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Numerate (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XtalPi (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BenevolentAI (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovista (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Certara (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cloud Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XtalPi (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atomwise (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exscientia (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Medicine (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iktos (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cradle (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations